Pharmacogenomics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2032)

Pharmacogenomics Market Trends & Growth Drivers

Technological Advancements in Pharmacogenomics Are Trending

• The key trend in the pharmacogenomics market is the adoption of advanced technology for both isolating and determining the sequence of the DNA, as well as interpret the findings.
• The most prominent among these technologies is , which can sequence hundreds of DNA in one go, thereby saving time and costs.
• It can be used to sequence the entire genome or a specific DNA of a person, enabling higher accuracy in identifying the variations in the genes.
• Since the data this technology is voluminous and complex, effective analysis tools with AI and ML technologies are being used increasingly.
• These tools help clinicians and researchers in identifying patterns and weighing them against historical trends to predict how a patient’s body will respond to a particular drug.

Growing Rate of Adverse Drug Reactions To Boost Market Growth

• Adverse drug reactions are the unwanted effects of a particular medication occurring during clinical use.
• Moreover, they can last long, thus adversely affecting a patient’s quality of life. In extreme cases, ADRs can result in morbidity and mortality.
• The increasing number of drugs in the market, growing geriatric population, and booming trend of polypharmacy are consistently propelling the prevalence of ADRs around the world.
• According to an article, in the U.S., 3% to 7% of all the hospitalizations are due to ADRs.
• These events occur during 10% to 20% of the hospitalizations, and about 10% to 20% of them are severe.
• The rapid increase in the number of cases of ADRs is propelling the demand for better treatment regimens.
• Precision medicine and pharmacogenomics provide a viable solution to this problem, by identifying patients in need of specific therapeutic modules that will provide beneficial treatment and reduce/completely negate the chances of any ADR.
• With proven efforts being documented in resolving such stark issues, there has been a massive improvement in the pharmacogenomics market growth prospects worldwide.

High-Multiplexing Is Major Opportunity Area

• High multiplexing is the most-opportunistic area for the market growth, particularly in applications such as infectious disease testing, genetic analysis, and .
• The clinical value of new, multiplex molecular diagnostics tests has been explicitly demonstrated in instances such as the 2009 H1N1 influenza pandemic, BCR-ABL genotyping in adult leukemia, and real-time detection of the causative pathogens of sepsis.
• Advanced multiplex molecular diagnostics technology has the potential to enable novel precision medicine approaches, such as multi-omics tests, that allow for the scrutiny of a patient’s biomarker map, to guide individualized therapeutic regimens, thus enabling superior pharmacogenomic capabilities.
• According to the FDA, in vitro diagnostic (IVDs) tests that are directly marketed to consumers without involving healthcare providers are referred to as direct-to-consumer (DTC) tests.
• These tests generally request the consumer to collect a specimen (saliva or urine, or others) and then send it directly to the company for testing and analysis.
• The availability of DTC testing is expanding the number of people who are now capable of acquiring genetic information regarding themselves.
• In addition, with the FDA regulations regarding the security of customers’ genetic information in place, this provides one of the biggest opportunities to the key stakeholders.

Pharmacogenomics Market Analysis

Service Insights

In 2024, genotyping services hold the dominating market share. This is mainly attributable to the recommendations of health providers all over the world for procuring individual genomic profiles, to cater to the constantly evolving healthcare demands. Additionally, targeted genotyping technologies are used by the majority of pharmacogenetic testing laboratories to clinically screen for particular variants with well-known drug–gene interactions.

Moreover, pharmacogenomics demonstrates the potential of customized treatment for patients with a variety of disorders, especially those who require several therapeutic interventions. Because of the recent advances in deciphering the human genome sequence, the usage of high-throughput genotyping technology has reduced the overall genetic testing costs and enabled the inclusion of genotype-specific dosage recommendations in drug package inserts, allowing pharmacogenomics to be integrated into clinical practice.

Pharmacogenetic testing is the fastest-growing category because it provides information about genes to help healthcare providers choose the most-effective and easily tolerable medicine and dosage. The tests use a sample of saliva (spit), blood, or cells swabbed from the cheek. Moreover, since the outburst of precision medicine initiatives has there been an evolutionarily increasing demand for targeted treatment and an increasing need to address the escalating incidence and severity of both infectious diseases and neurology. After initial considerations for overall genomic predispositions, the demand for pharmacogenetic testing is also increasing.

These services are part of the research scope:

• Genotyping (Largest Category)
• SNP Identification
• Pharmacogenetic Testing (Fastest-Growing Category)
• Others

Application Insights

The oncology category dominates the market owing to the rapid adoption of pharmacogenomics in drug development, especially in advanced economies; high incidence of different types of cancers, and rising demand for biologics and drugs based on monoclonal antibodies to treat tumors.

Moreover, cancer pharmacogenomics has aided a number of key advancements in cancer treatment. For instance, Irinotecan is a chemotherapeutic drug used to treat colon cancer. Genetic polymorphisms produce a deficiency of the UGT1A1 enzyme in some persons. This enzyme is in charge of breaking down irinotecan. Higher levels of irinotecan stay in the body when UGT1A1 is inadequate. This could result in serious side effects and even fatality. In this situation, a pharmacogenomic test known as the UGT1A1 test is performed to determine which individuals have this genetic variant, so a decreased irinotecan dose can be prescribed.

The neurology category is expected to register the highest CAGR during the forecast period. This can be due to the increasing incidences of neurological diseases. For instance, in Germany, more than 2 million people have dementia or Parkinson's disease, including younger people. The adoption of advanced imaging techniques, phenotype identification methods that utilize genetic knowledge, and biomarkers enable in-depth research on several neurological disorders, thereby enhancing treatment efficacy.

We have studied the following applications:

• Oncology (Largest Category)
• Infectious Diseases
• Neurology (Fastest-Growing Category)
• Cardiovascular Diseases
• Others

Technology Insights

The PCR technology contributed 30% revenue in 2024. This category is growing due to the fact that PCR uses a small sample for analysis, in order to detect microbial agents, and the process takes about 4–8 hours, which is roughly three times faster than other methods. Additionally, multiplex PCR is a form of PCR that may amplify several DNA sequences in a single reaction. It has been routinely utilized to identify a variety of antibiotic genes. Additionally, PCR has demonstrated higher sensitivity and positivity rates than culture and stains for both fungi and bacteria.

The DNA sequencing/NGS category holds largest share in the market. This will primarily be due to the increasing focus on sequencing analysis for different genomic patterns. Moreover, sequencing methods have had a strong impact on healthcare services worldwide. With genomic information coming to the forefront of disease diagnosis, treatment modalities have undergone massive changes. Further, sequencing technology offers, long-insert paired-end reads for efficient de novo sequencing, sequence assembly, and other applications, as well as a short-insert paired-end capability for high-resolution genome sequencing.

The below-mentioned technologies have been analyzed:

• Polymerase Chain Reaction (PCR) (Fastest-Growing Category)
• Microarray
• DNA Sequencing/Next Generation Sequencing (NGS) (Largest Category)
• Others

End User Insights

Research organizations hold the largest share in the pharmacogenomics market, of 40%. This is due to the growing focus on research pertaining to the development of pharmacogenomic tests based on molecular assay technologies, the increasing prominence of targeted therapeutics in the field of oncology, and the rising number of industry-academia collaborations, among others.

Diagnostic centers are projected to flourish at the highest growth rate in the years ahead. With the increasing incidence of both infectious diseases and cancer, diagnostic centers need to be well-equipped. With the extensive research culminating in highly advanced assays and systems, diagnostic centers account for the highest usage of this technology. Additionally, technological advancements have revolutionized the services provided by diagnostic centers, thereby driving the patient footfall at these places.

The segment is categories as follows:

• Research Organizations (Largest Category)
• Pharmaceutical Companies
• Diagnostic Centers (Fastest-Growing Category)
• Others

Regional Analysis

• In 2024, the North American pharmacogenomics market is the largest with 45% revenue contribution.
• The increase in the adoption of pharmacogenomic practices in the region is driven by the government initiatives for incorporating targeted medicine approaches in the mainstream healthcare system.
• Moreover, the U.S. Food and Drug Administration (FDA) and the Clinical Laboratory Improvement Amendments (CLIA) have been at the forefront of the development of effective and appropriate guidelines and policies in order to propel the adoption of pharmacogenomic tests by end users.
• Additionally, the presence of leading market players in the U.S., coupled with the significant adoption of advanced pharmacogenomic solutions in the field of research, is resulting in the booming market.
• APAC will have the highest CAGR, of 8%, during this decade owing to the rise in the incidence of infectious and chronic ailments, growing healthcare expenditure, advancing genomics technologies, improving infrastructure for research, and favorable government initiatives.
• The region is home to a large and growing population, with which comes an increase in the prevalence of chronic diseases.
• Non-communicable diseases account for almost two-thirds of all the deaths in the WHO South-East Asian Region.
• Nearly half of these deaths occur prematurely between the ages of 30 and 69 years.

Below is the regional breakdown of the market:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest and Fastest-Growing Country Market)
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China
  • India (Fastest-Growing Country Market)
  • Japan (Largest Country Market)
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest and Fastest-Growing Country Market)
  • Mexico
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Largest and Fastest-Growing Country Market)
  • South Africa
  • Rest of MEA

Pharmacogenomics Market Share

The market is fragmented because it is still an evolving field, offering a wide array of companies the room to grow, compete, and prosper. A variety of technologies, such as PCR, phenotyping, and NGS, are used to studying the genes, with service providers differing on the ones they use. Additionally, diverse therapeutic areas for which pharmacogenomic analyses are required fragmented the landscape, as market players generally specialize in a few of these. Another factor behind this fragmentation is the varying regulatory scenario for pharmaceuticals across countries.

Pharmacogenomics Market Company News

• In October 2024, Thermo Fisher Scientific Inc. received the FDA approval for its NGS-based companion diagnostic test to enable targeted therapies for grade 2 IDH-mutant glioma.
• In October 2024, F. Hoffmann-La Roche Ltd. obtained the CE mark for the companion diagnostic test, developed in partnership with Laboratory Corporation of America Holdings, to identify gastric and gastroesophageal junction cancer patients who can be given the VYLOY targeted therapy.
• In October 2024, Myriad Genetics Inc. entered into a partnership with jscreen to enhance access to genetic testing and promote health equity. Under the partnership, jscreen will use the reproductive genetics and hereditary cancer products of Myriad Genetics—Foresight Carrier Screen and MyRisk with RiskScore— for its genetic care navigation and education program.
• In October 2024, QIAGEN N.V. launched PGXI, knowledge base of pharmacogenomics insights sourced from the FDA, Dutch Pharmacogenetics Working Group (DPWG), Clinical Pharmacogenetics Implementation Consortium (CPIC), PubMed, and Pharmacogene Variation Consortium (PharmVar).